Added to YB: 2026-07-24
Pitch date: 2026-07-22
QURE [neutral]
uniQure N.V.
-1.18%
current return
Author Info
Warden Capital is a real estate oriented investment firm sharing musings on public and private commercial real estate markets. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$2.8B
Pitch Price
$39.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
-16.13
P/E
-11.50
EV/Sales
150.08
Sector
Biotechnology
Category
special_situation
War Cap Q2 2026 update - uniQure N.V.
QURE (holding update): Biotech w/ promising Huntington's disease gene therapy targeting striatum. Bought ~$20s, doubled down ~$9 (below cash) after FDA refused accelerated approval. New FDA leadership now allowing accelerated filing; stock ~$40s. Roche trial pull validates selective approach vs whole-brain rivals. Trimmed post-pop but large position; sees upside on full approval.
Read full article (2 min)